As inhibition of the IL-6 axis is associated with higher risk for dyslipidaemia, two studies investigated the effect of TCZ on lipid-associated CV risk markers, reporting that median total-cholesterol, low-density lipoprotein-cholesterol and triglyceride levels increased in TCZ treatment arms when compared with placebo and ADA. Here, IL6 is linked to inherited lipid metabolism disorder.